StonvexLoading…
StonvexStonvexStonvexCore line items from CTS's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $541.32M | $514.76M | $550.42M | $586.87M |
Operating Income | $82.64M | $71.19M | $75.05M | $93.01M |
Net Income | $65.32M | $55.47M | $60.53M | $59.58M |
EPS (Diluted) | $2.19 | $1.81 | $1.92 | $1.85 |
Total Assets | $764.31M | $765.43M | $741.17M | $748.49M |
Total Liabilities | $212.53M | $237.22M | $214.34M | $242.26M |
Cash & Equivalents | $82.30M | $94.33M | $163.88M | $156.91M |
Free Cash Flow OCF − CapEx | $86.37M | $79.60M | $74.07M | $106.86M |
Shares Outstanding | 28.76M | 30.03M | 30.82M | 31.68M |